drugset / Trial / NCT00006014

SU5416 in Treating Patients With Malignant Mesothelioma

NCT00006014

Phase 2 Completed 45 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to the tumor.

Timeline

Start
2000-08
Primary completion
2007-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject semaxanib Small molecule Intravenous